Last reviewed · How we verify
complicated intra-abdominal infections caused by Klebsiella oxytoca
Approved treatments
- Xerava · Tetraphase Pharms
Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- complicated intra-abdominal infections caused by Klebsiella oxytoca patent landscape — cliff calendar, originator estates, attackable patents
- complicated intra-abdominal infections caused by Klebsiella oxytoca treatment landscape brief
- complicated intra-abdominal infections caused by Klebsiella oxytoca treatment updates RSS
Frequently asked questions about complicated intra-abdominal infections caused by Klebsiella oxytoca
What drugs treat complicated intra-abdominal infections caused by Klebsiella oxytoca?
Tracked treatments include Xerava.
What is the treatment for complicated intra-abdominal infections caused by Klebsiella oxytoca?
Standard treatment for complicated intra-abdominal infections caused by Klebsiella oxytoca includes Xerava. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: complicated intra-abdominal infections caused by Klebsiella oxytoca patent cliff · complicated intra-abdominal infections caused by Klebsiella oxytoca CI report
- Treatment: Xerava · Tetraphase Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing